Maviret

European regulators expand use of AbbVie's two-month hep C regimen
Endpoints
Fri, 03/6/20 - 10:39 am
AbbVie
Europe
hepatitis C
Maviret
NICE nods for AbbVie in hep C and Novartis in lung cancer
Pharma Times
Sun, 12/10/17 - 09:53 am
NICE
AbbVie
hepatitis C
Maviret
Novartis
Zykadia
ALK-positive non-small cell lung cancer
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Sat, 06/24/17 - 09:11 am
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda